Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 19:28:e934255.
doi: 10.12659/MSM.934255.

Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling

Affiliations
Review

Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling

Shichun Shen et al. Med Sci Monit. .

Abstract

Reperfusion therapy is the optimal therapy for acute myocardial infarction (AMI), but acute inflammatory injury and chronic heart failure (HF) after myocardial ischemia and reperfusion (MI/R) remain the leading cause of death after AMI. Pyroptosis, a newly discovered form of cell death, has been proven to play a significant role in the acute reperfusion process and the subsequent chronic process of ventricular remodeling. Current research shows that multiple stimuli activate the pyroptotic signaling pathway and contribute to cell death and nonbacterial inflammation after MI/R. These stimuli promote the assembly of the nucleotide-binding and oligomerization-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome by activating NLRP3. The mature NLRP3 inflammasome cleaves procaspase-1 to active caspase-1, which leads to mature processing of interleukin (IL)-18, IL-1ß, and gasdermin D (GSDMD) protein. That eventually results in cell lysis and generation of nonbacterial inflammation. The present review summarizes the mechanism of NLRP3 inflammasome activation after MI/R and discusses the role that NLRP3-mediated pyroptosis plays in the pathophysiology of MI/R injury and ventricular remodeling. We also discuss potential mechanisms and targeted therapy for which there is evidence supporting treatment of ischemic heart disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1
Figure 1
A dual-signal model mediated the activation process of the nucleotide-binding and oligomerization-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome. The first step was stimulating promotion of nuclear factor-κB into the nucleus to regulate the transcription and translation of the NLRP gene in the nucleus and release it into the cytoplasm. The second step was divided into the non-canonical caspase-11-mediated and canonical NLRP3 inflammasome-mediated pyroptosis pathways. Adobe Illustrator CC 2019 (Adobe Software, San Jose, California, United States) was used for drawing.
Figure 2
Figure 2
Potential sources and consequences of nucleotide-binding and oligomerization-like receptor pyrin domain-containing protein 3 (NLRP3) activation signaling pathway during myocardial ischemia and reperfusion (MI/R). MI/R promotes potassium efflux, which directly increases the expression of NIMA-related kinase 7 (NEK7) to form the NLRP3 complex. MI/R promotes sodium-hydron exchange and sodium-calcium exchange and sarcoplasmic reticulum and endoplasmic reticulum release calcium. Calcium overload causes mitochondrial instability and NLRP3 inflammasome activation. MI/R promotes mitochondrial dysfunction and reactive oxygen species (ROS) production. ROS activates the NLRP3 inflammasomes by regulating nuclear factor-κB, caspase-11, and thioredoxin-interacting protein. Adobe Illustrator CC 2019 (Adobe Software, San Jose, California, United States) was used for drawing.

References

    1. Khan MA, Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: Results from the global burden of disease study. Cureus. 2020;12(7):e9349. - PMC - PubMed
    1. Versluis A, Bank AJ, Douglas WH. Fatigue and plaque rupture in myocardial infarction. J Biomech. 2006;39(2):339–47. - PubMed
    1. Kones R. Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag. 2010;6:635–56. - PMC - PubMed
    1. Heusch G. Myocardial ischemia: Lack of coronary blood flow or myocardial oxygen supply/demand imbalance? Circ Res. 2016;119(2):194–96. - PubMed
    1. Amani H, Habibey R, Hajmiresmail S, et al. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia-reperfusion injuries. J Mater Chem B. 2017;5(48):9452–76. - PubMed

MeSH terms

Substances